RxDoctor Payments Data

Melissa Mason

Psychiatric/Mental Health · Bellevue, WANPI 1932796331

Payments from drug & device makers

$2,610in general payments, 2019–2025

Across 54 payments — averaging $48.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuronetics, Inc.$1K
  • Axsome Therapeutics, Inc.$311
  • E.r. Squibb & Sons, L.L.C.$178
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$159
  • Otsuka America Pharmaceutical, Inc.$137
  • Alkermes, Inc.$131
  • plus $311 from 6 others

What the payments were for

  • Travel & lodging$71327%
  • Food & beverage$1,89773%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,610 in reported general payments places this provider in the 85th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$32,887
Medicare patients
42
Services billed
316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl37$53,559
Vilazodone Hcl23$3,597
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine84$3,167
Olanzapine87$2,715
Clozapine37$2,603
Lamotrigine154$2,340
Duloxetine Hcl83$1,826
Bupropion XlBupropion Hcl77$1,611
Quetiapine Fumarate84$1,370
Clonazepam156$1,338
Mirtazapine77$1,251
Gabapentin68$1,045
Escitalopram Oxalate80$995
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine29$946
Aripiprazole39$920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$126$53,55937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 931 psychiatric/mental health providers in Washington.

Other psychiatric/mental health in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →